The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat adults with moderately to severely active ulcerative colitis (UC ...

Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with ...

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson ...

Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

At the end of Q4 2024, 18 billionaires held positions in Johnson & Johnson (NYSE:JNJ), worth over $2.9 billion collectively.

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share.

Newer agents with non-TNF targets including guselkumab (Tremfya), risankizumab (Skyrizi), and anifrolumab (Saphnelo) should be avoided unless no effective alternatives can be found. Finally ...